Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Eplerenone (Inspra - Pfizer Canada Inc.) new indication: NYHA class II heart failure. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDEC final recommendation. 2014 Authors' conclusions Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that eplerenone not be listed at the submitted price for patients with New York Heart Association (NYHA) class II systolic chronic heart failure. Indexing Status Subject indexing assigned by CRD MeSH Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32014000749 Date abstract record published 08/07/2014 |